Roche has secured CE Mark approval for its cobas bacterial vaginosis/candida vaginitis (BV/CV) assay to support the diagnosis ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...

With the approval, the company's automated clinical mass spec system, the Cobas I 601 analyzer, features an in vitro diagnostic menu of 39 tests.

Roche AG received CE mark for its cobas Bacterial Vaginosis/Candida Vaginitis assay, which will help to improve accuracy in detecting vaginitis in women. The molecular test identifies specific ...

The test helps diagnose infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis.

Weight-loss drug developers line up to tap lucrative market as competition heats up The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as ...

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as ...